CYTOF 20-F/A

Altamira Therapeutics Ltd. (CYTOF)

20-F/A 2024-07-01 For: 2023-12-31

View Original

Added on August 22, 2026

Search and read filings like this one from Claude or ChatGPT with the SEC filings MCP server →

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Shares, par value USD 0.002 per share		CYTO		The Nasdaq Stock Market LLC

	Large accelerated filer ☐		Accelerated filer ☐		Non-accelerated filer ☒
					Emerging Growth Company ☐

	International Financial Reporting
	Standards as issued by the International
U.S. GAAP ☐	Accounting Standards Board ☒	Other ☐

1.1		Memorandum of Continuance and Corporate Actions of the registrant (incorporated herein by reference to exhibit 3.1 of the Altamira Therapeutics Ltd. registration statement on Form F-1 (Registration No. 333-269823) filed with the Commission on March 7, 2023)
1.2		Bye-laws of the Registrant (incorporated herein by reference to exhibit 3.2 of the Altamira Therapeutics Ltd. registration statement on Form F-1 (Registration No. 333-269823) filed with the Commission on February 16, 2023
2.1		Form of Registration Rights Agreement between Auris Medical Holding AG and the shareholders listed therein (incorporated by reference to exhibit 4.1 of the Auris Medical Holding AG registration statement on Form F-1 (Registration no. 333-197105) filed with the Commission on July 21, 2014)
2.2		Warrant Agreement, dated as of March 13, 2018, between Auris Medical Holding AG and Hercules Capital, Inc. (incorporated by reference to exhibit 2.2 of the Auris Medical Holding AG Annual Report on Form 20-F filed with the Commission on March 22, 2018)
2.3		Registration Rights Agreement, dated as of October 10, 2017 between Auris Medical Holding AG and Lincoln Park Capital Fund, LLC (incorporated by reference to exhibit 10.3 of the Auris Medical Holding AG report on Form 6-K filed with the Commission on October 11, 2017)
2.4		Purchase Agreement, dated as of May 2, 2018 between Auris Medical Holding AG and Lincoln Park Capital Fund, LLC (incorporated by reference to exhibit 10.1 of the Auris Medical Holding AG report on Form 6-K filed with the Commission on May 2, 2018)
2.5		Registration Rights Agreement, dated as of May 2, 2018 between Auris Medical Holding AG and Lincoln Park Capital Fund, LLC (incorporated by reference to exhibit 10.2 of the Auris Medical Holding AG report on Form 6-K filed with the Commission on May 2, 2018)
2.6		Form of Pre-Funded Warrant (incorporated by reference to exhibit 4.6 of the Auris Medical Holding AG registration statement on Form F-1 (Registration no. 333-225676) filed with the Commission on July 12, 2018)
2.7		Form of Series A Warrant (incorporated by reference to exhibit 4.7 of the Auris Medical Holding AG registration statement on Form F-1 (Registration no. 333-225676) filed with the Commission on July 12, 2018)
2.8		Form of Series B Warrant (incorporated by reference to exhibit 4.8 of the Auris Medical Holding AG registration statement on Form F-1 (Registration no. 333-225676) filed with the Commission on July 12, 2018)
2.9		Form of Common Warrant (incorporated by reference to exhibit 4.1 of the Auris Medical Holding Ltd. report on Form 6-K filed with the commission on May 16, 2019)
2.10		Form of Pre-Funded Warrant (incorporated by reference to exhibit 4.2 of the Auris Medical Holding Ltd. report on Form 6-K filed with the commission on May 16, 2019)
2.11		Form of Common Warrant Agent Agreement (incorporated by reference to exhibit 4.3 of the Auris Medical Holding Ltd. report on Form 6-K filed with the commission on May 16, 2019)
2.12		Form of Pre-Funded Warrant Agent Agreement (incorporated by reference to exhibit 4.4 of the Auris Medical Holding Ltd. report on Form 6- K filed with the commission on May 16, 2019)
2.13**		Description of Securities Registered under Section 12 of the Exchange Act
2.14		Purchase Agreement, dated as of April 23, 2020 between Auris Medical Holding Ltd. and Lincoln Park Capital Fund, LLC (incorporated by reference to exhibit 10.1 of the Auris Medical Holding Ltd. report on Form 6-K furnished with the Commission on April 23, 2020)
2.15		Registration Rights Agreement, dated as of April 23, 2020 between Auris Medical Holding Ltd. and Lincoln Park Capital Fund, LLC (incorporated by reference to exhibit 10.2 of the Auris Medical Holding Ltd. report on Form 6-K furnished with the Commission on April 23, 2020)

2.16		Form of Warrant, dated as of September 9, 2022 (incorporated by reference to exhibit 4.1 of the Altamira Therapeutics Ltd. report on Form 6-K filed with the Commission on September 12, 2022)
2.17		Purchase Agreement, dated as of December 5, 2022 between Altamira Therapeutics Ltd. and Lincoln Park Capital Fund, LLC (incorporated by reference to exhibit 10.1 of the Altamira Therapeutics Ltd. report on Form 6-K filed with the Commission on December 5, 2022)
2.18		Registration Rights Agreement, dated as of December 5, 2022 between Altamira Therapeutics Ltd. and Lincoln Park Capital Fund, LLC (incorporated by reference to exhibit 10.2 of the Altamira Therapeutics Ltd. report on Form 6-K filed with the Commission on December 5, 2022)
2.19		Form of Common Warrant (incorporated by reference to exhibit 4.19 of the Altamira Therapeutics Ltd. registration statement on Form F-1/A filed with the Commission on July 5, 2023)
2.20		Form of Pre-funded Warrant (incorporated by reference to exhibit 4.20 of the Altamira Therapeutics Ltd. report on Form F-1/A filed with the Commission on July 5, 2023)
2.21		Form of Placement Agent Warrant (incorporated by reference to exhibit 4.21 of the Altamira Therapeutics Ltd. report on Form F-1/A filed with the Commission on July 5, 2023)
4.1†		Collaboration and License Agreement, dated October 21, 2003, between Auris Medical AG and Xigen SA (incorporated by reference to exhibit 10.1 of the Auris Medical Holding AG registration statement on Form F-1 (Registration no. 333-197105) filed with the Commission on June 27, 2014)
4.2†		Co-Ownership and Exploitation Agreement, dated September 29, 2003, between Auris Medical AG and INSERM (incorporated by reference to exhibit 10.2 of the Auris Medical Holding AG registration statement on Form F-1 (Registration no. 333-197105) filed with the Commission on June 27, 2014)
4.3		Form of Indemnification Agreement (incorporated by reference to exhibit 99.4 of the Auris Medical Holding AG report on Form 6-K filed with the Commission on May 11, 2016)
4.4		Stock Option Plan A (incorporated by reference to exhibit 10.11 of the Auris Medical Holding AG registration statement on Form F-1 (Registration no. 333-197105) filed with the Commission on June 27, 2014)
4.5		Stock Option Plan C (incorporated by reference to exhibit 10.12 of the Auris Medical Holding AG registration statement on Form F-1 (Registration no. 333-197105) filed with the Commission on June 27, 2014)
4.6		Equity Incentive Plan, as amended (incorporated by reference to exhibit 99.1 to the Auris Medical Holding AG registration statement on Form S-8 (Registration no. 333-217306) filed with the Commission on April 14, 2017)
4.7		English language translation of Lease Agreement between Auris Medical AG and PSP Management AG (incorporated by reference to exhibit 4.8 of the Auris Medical Holding AG Annual Report on Form 20-F filed with the Commission on March 14, 2017)
4.8		Controlled Equity OfferingSM Sales Agreement, dated as of June 1, 2016, between Auris Medical Holding AG and Cantor Fitzgerald & Co. (incorporated by reference to exhibit 1.1 of the Auris Medical Holding AG report on Form 6-K filed with the Commission on June 1, 2016)
4.9		Share Lending Agreement, dated as of June 1, 2016, between Thomas Meyer and Cantor Fitzgerald & Co. (incorporated by reference to exhibit 10.1 of the Auris Medical Holding AG report on Form 6-K filed with the Commission on June 1, 2016)
4.10		Loan and Security Agreement, dated as of July 19, 2016, between Auris Medical Holding AG, the several banks and other financial institutions or entities from time to time parties to the agreement and Hercules Capital, Inc. (incorporated by reference to exhibit 10.1 of the Auris Medical Holding AG report on Form 6-K filed with the Commission on July 19, 2016)
4.11		Consent and Waiver, dated as of March 8, 2018, between Auris Medical Holding AG, the several banks and other financial institutions or entities from time to time parties to the agreement and Hercules Capital, Inc. (incorporated by reference to exhibit 4.12 of the Auris Medical Holding AG Annual Report on Form 20-F filed with the Commission on March 22, 2018)
4.12		Joinder Agreement dated as of March 13, 2018 to the Loan and Security Agreement, dated as of July 19, 2016, between Auris Medical Holding AG, the several banks and other financial institutions or entities from time to time parties to the agreement and Hercules Capital, Inc. (incorporated by reference to exhibit 4.13 of the Auris Medical Holding AG Annual Report on Form 20-F filed with the Commission on March 22, 2018)
4.13		Share Pledge Agreement, dated July 19, 2016, between Auris Medical Holding AG and Hercules Capital, Inc. (incorporated by reference to exhibit 10.3 of the Auris Medical Holding AG report on Form 6-K filed with the Commission on July 19, 2016)
4.14		Claims Security Assignment Agreement, dated July 19, 2016, between Auris Medical Holding AG and Hercules Capital, Inc. (incorporated by reference to exhibit 10.4 of the Auris Medical Holding AG report on Form 6-K filed with the Commission on July 19, 2016)
4.15		Bank Account Claims Security Assignment Agreement, dated July 19, 2016, between Auris Medical Holding AG and Hercules Capital, Inc. (incorporated by reference to exhibit 10.5 of the Auris Medical Holding AG report on Form 6-K filed with the Commission on July 19, 2016)
4.16		Purchase Agreement, dated as of October 10, 2017 between Auris Medical Holding AG and Lincoln Park Capital Fund, LLC (incorporated by reference to exhibit 10.1 of the Auris Medical Holding AG report on Form 6-K filed with the Commission on October 11, 2017)

4.17		Purchase Agreement, dated as of October 10, 2017 between Auris Medical Holding AG and Lincoln Park Capital Fund, LLC (incorporated by reference to exhibit 10.2 of the Auris Medical Holding AG report on Form 6-K filed with the Commission on October 11, 2017)
4.18		Placement Agency Agreement, dated as of January 28, 2018, between Auris Medical Holding AG and Ladenburg Thalmann & Co. Inc. (incorporated by reference to exhibit 1.1 of the Auris Medical Holding AG report on Form 6-K filed with the Commission on January 30, 2018)
4.19		Securities Purchase Agreement, dated as of January 26, 2018 by and among Auris Medical Holding AG and the investors named therein (incorporated by reference to exhibit 10.1 of the Auris Medical Holding AG report on Form 6-K filed with the Commission on January 30, 2018)
4.20		Agreement and Plan of Merger, dated as of February 9, 2018 by and among Auris Medical Holding AG and Auris Medical NewCo Holding AG (incorporated by reference to exhibit 99.3 of the Auris Medical Holding AG report on Form 6-K filed with the Commission on February 9, 2018)
4.21		Share Transfer Agreement, dated as of February 9, 2018 by and between Thomas Meyer and Auris Medical Holding AG (incorporated by reference to exhibit 4.22 of the Auris Medical Holding AG Annual Report on Form 20-F filed with the Commission on March 22, 2018)
4.22		Sales Agreement, dated as of November 30, 2018, between Auris Medical Holding AG and A.G.P./Alliance Global Partners (incorporated by reference to exhibit 1.1 of the Auris Medical Holding AG report on Form 6-K filed with the Commission on November 30, 2018)
4.23		Form of Indemnification Agreement (incorporated by reference to exhibit 10.23 of the Auris Medical Holding Ltd. registration statement on Form F-1 (Registration no. 333-229465) filed with the Commission on March 20, 2019)
4.24		Amendment No. 1 to Sales Agreement, dated as of April 5, 2019, between Auris Medical Holding Ltd. and A.G.P./Alliance Global Partners (incorporated by reference to exhibit 1.1 of the Auris Medical Holding Ltd. report on Form 6-K filed with the Commission on April 5, 2019)
4.25		Convertible Loan Agreement, dated as of September 7, 2020, by and among Auris Medical Holding Ltd., Altamira Medica AG and FiveT Capital Holding AG (incorporated by reference to exhibit 99.1 of the Auris Medical Holding Ltd. report on Form 6-K furnished with the Commission on September 8, 2020)
4.26†		Agreement and Plan of Merger, dated June 1, 2021, by and among Auris Medical Holding Ltd., Auris Medical Inc., Trasir Therapeutics, Inc., and each of the stockholders of Trasir Therapeutics, Inc. (incorporated by reference to exhibit 2.1 of the Auris Medical Holding Ltd. report on Form 6-K furnished with the Commission on June 3, 2021)
4.27†		Exclusive License Agreement, dated December 11, 2020, by and between Washington University and Trasir Therapeutics, Inc. (incorporated by reference to exhibit 10.1 of the Auris Medical Holding Ltd. report on Form 6-K furnished with the Commission on June 3, 2021)
4.28		Convertible Loan Agreement, dated as of February 4, 2022, by and among Altamira Therapeutics Ltd. and FiveT Investment Management Ltd. (incorporated by reference to exhibit 99.1 of the Altamira Therapeutics Ltd. report on Form 6-K furnished with the Commission on February 8, 2022)
4.29†		Licensing & Distribution Agreement, dated February 28, 2022, by and between Altamira Medica Ltd. and Nuance Pharma Limited. (incorporated by reference to exhibit 10.1 of the Altamira Therapeutics Ltd. report on Form 6-K furnished with the Commission on March 4, 2022)
4.30		Loan Agreement, dated as of September 9, 2022, by and among Altamira Therapeutics Ltd. and the Lenders (incorporated by reference to exhibit 99.1 of the Altamira Therapeutics Ltd. report on Form 6-K filed with the Commission on September 12, 2022)
4.31		Share Purchase Agreement, dated October 19, 2022, by and between Altamira Therapeutics Ltd. and the purchaser party thereto (incorporated by reference to exhibit 99.1 of the Altamira Therapeutics Ltd. report on Form 6-K filed with the Commission on October 24, 2022)
4.32		Option Agreement, dated October 19, 2022, by and between Altamira Therapeutics Ltd., Zilentin AG and the other party thereto (incorporated by reference to exhibit 99.2 of the Altamira Therapeutics Ltd. report on Form 6-K filed with the Commission on October 24, 2022)

4.33		Amendment No. 1 to Convertible Loan Agreement, between Altamira Therapeutics Ltd. and FiveT Investment Management Ltd. (incorporated by reference to exhibit 99.1 of the Altamira Therapeutics Ltd. report on Form 6-K filed with the Commission on January 27, 2023)
4.34		Amendment No. 2 to Convertible Loan Agreement, between Altamira Therapeutics Ltd. and FiveT Investment Management Ltd. (incorporated by reference to exhibit 99.1 of the Altamira Therapeutics Ltd. report on Form 6-K filed with the Commission on March 9, 2023)
4.35		Amendment No. 3 to Convertible Loan Agreement, between Altamira Therapeutics Ltd. and FiveT Investment Management Ltd. (incorporated herein by reference to exhibit 10.22 of the Altamira Therapeutics Ltd. registration statement on Form F-1 (Registration No. 333-269823) filed with the Commission on March 23, 2023)
4.36		Amendment No. 4 to Convertible Loan Agreement, between Altamira Therapeutics Ltd. and FiveT Investment Management Ltd. (incorporated herein by reference to exhibit 10.23 of the Altamira Therapeutics Ltd. registration statement on Form F-1 (Registration No. 333-269823) filed with the Commission on March 27, 2023)
4.37		Amendment No. 5 to Convertible Loan Agreement, between Altamira Therapeutics Ltd. and FiveT Investment Management Ltd. (incorporated by reference to exhibit 99.1 of the Altamira Therapeutics Ltd. report on Form 6-K filed with the Commission on April 3, 2023)
4.38		Amendment No. 6 to Convertible Loan Agreement, between Altamira Therapeutics Ltd. and FiveT Investment Management Ltd.
4.39		Amendment No. 7 to Convertible Loan Agreement, between Altamira Therapeutics Ltd. and FiveT Investment Management Ltd. (incorporated by reference to exhibit 99.1 of the Altamira Therapeutics Ltd. report on Form 6-K filed with the Commission on April 13, 2023)
4.40		Form of Amendment No. 1 to Loan Agreement, dated December 28, 2022 (incorporated by reference to exhibit 4.40 of the Altamira Therapeutics Ltd. Annual Report on Form 20-F filed with the Commission on May 16, 2023)
4.41		Amendment No. 1 to Loan Agreement, between Altamira Therapeutics Ltd. and the Lenders (incorporated by reference to exhibit 10.41 of the Altamira Therapeutics Ltd. report on Form F-1/A filed with the Commission on June 16, 2023)
4.42		Amendment No. 2 to Loan Agreement, between Altamira Therapeutics Ltd. and the Lenders (incorporated by reference to exhibit 4.41 of the Altamira Therapeutics Ltd. Annual Report on Form 20-F filed with the Commission on May 16, 2023)
4.43		Convertible Loan Agreement, dated as of May 1, 2023, by and among Altamira Therapeutics Ltd. and FiveT Investment Management Ltd. (incorporated by reference to exhibit 99.1 of the Altamira Therapeutics Ltd. report on Form 6-K filed with the Commission on May 2, 2023)
4.44		Form of Securities Purchase Agreement (incorporated by reference to exhibit 10.1 of the Altamira Therapeutics Ltd. report on Form 6-K filed with the Commission on July 11, 2023)
4.45†		Share Purchase Agreement, dated November 17, 2023, by and between Auris Medical AG and the Purchaser (incorporated by reference to exhibit 2.1 of the Altamira Therapeutics Ltd. report on Form 6-K filed with the Commission on November 21, 2023)
4.46		Form of Warrant Inducement Agreement, dated December 7, 2023 (incorporated by reference to exhibit 10.1 of the Altamira Therapeutics Ltd. report on Form 6-K filed with the Commission on December 8, 2023)
4.47		At the Market Offering Agreement, dated as of January 19, 2024, by and between Altamira Therapeutics Ltd. and H.C. Wainwright & Co., LLC (incorporated by reference to exhibit 1.1 of the Altamira Therapeutics Ltd. report on Form 6-K filed with the Commission on January 19, 2024)
8.1**		List of subsidiaries
12.1*		Certification of Thomas Meyer pursuant to 17 CFR 240.13a-14(a)
12.2*		Certification of Marcel Gremaud pursuant to 17 CFR 240.13a-14(a)
13.1*		Certification of Thomas Meyer pursuant to 17 CFR 240.13a-14(b) and 18 U.S.C.1350
13.2*		Certification of Marcel Gremaud pursuant to 17 CFR 240.13a-14(b) and 18 U.S.C. 1350
15.1**		Consent of Deloitte AG
15.2**		Consent of BDO AG
15.3*		Consent of BDO AG
97.1**		Compensation Recovery Policy
101.INS*		Inline XBRL Instance Document
101.SCH*		Inline XBRL Taxonomy Extension Schema Document
101.CAL*		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB*		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*		Inline XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF*		Inline XBRL Taxonomy Extension Definition Linkbase Document
104*		Cover Page Interactive Data File formatted as Inline XBRL and contained in Exhibit 101

	ALTAMIRA THERAPEUTICS LTD.

	By:	/s/ Thomas Meyer
		Name:	Thomas Meyer
		Title:	Chief Executive Officer

Date: July 1, 2024

Audited Consolidated Financial Statements — Altamira Medica AG

As of December 31, 2023 and for the period of January 1 to December 31, 2023.

Independent Auditor's Report (BDO AG, Zurich, Switzerland, PCAOB ID # 5988)	F-43
Consolidated Statement of Profit or Loss and Other Comprehensive Income / (Loss)	F-45
Consolidated Statement of Financial Position	F-46
Consolidated Statement of Changes in Deficit	F-47
Consolidated Statement of Cash Flows	F-48
Notes to the consolidated financial statements	F-49

BDO AG

/s/ Christoph Tschumi		/s/ Marc Furlato
Christoph Tschumi		Marc Furlato

	Note	2023
Revenue	14		158,213
Cost of sales	15		(225,889	)
Gross profit/(loss)			(67,676	)
Other operating income	16		134,075
Research and development	17		(1,425,373	)
Selling, general and administrative	18		(372,479	)
Operating loss			(1,731,453	)
Finance income	19		287,032
Finance expense	19		(433,956	)
Loss before tax			(1,878,377	)
Income tax gain	20		98,872
Net loss attributable to owners of the Company			(1,779,505	)
Items that are or may be reclassified to profit or loss
Foreign currency translation differences, net of taxes of CHF 0			138,583
Other comprehensive income, net of taxes of CHF 0			138,583
Total comprehensive loss attributable to owners of the Company			(1,640,922	)

		December 31,
	Note	2023
ASSETS
Non-current assets
Other non-current financial assets	5		102,157
Total non-current assets			102,157
Current assets
Inventories	6		331,061
Trade receivables			100,392
Other receivables	7		282,816
Prepayments	8		171,995
Cash and cash equivalents	9		490,388
Total current assets			1,376,652

Total assets			1,478,809

EQUITY AND LIABILITIES
Deficit
Share capital	10		3,000,000
Share premium			17,494,413
Other reserves			138,583
Accumulated deficit			(20,726,382	)
Total shareholders’ deficit attributable to owners of the Company			(93,386	)

Non-current liabilities
Deferred income	13		932,200
Deferred tax liabilities	20		57,211
Total non-current liabilities			989,411
Current liabilities
Loan	22		18,905
Trade and other payables	11		327,582
Contract liabilities			175,457
Accrued expenses	12		60,840
Total current liabilities			582,784
Total liabilities			1,572,195
Total equity and liabilities			1,478,809

						Currency
		Share		Share		Translation		Accumulated			Total
	Note	Capital		Premium		Reserve		Deficit			Deficit
As of January 1, 2023	10		3,000,000		-		-		(18,946,877	)		(15,946,877	)
Total comprehensive loss
Net loss			-		-		-		(1,779,505	)		(1,779,505	)
Other comprehensive income			-		-		138,583		-			138,583
Total comprehensive loss			-		-		138,583		(1,779,505	)		(1,640,922	)

Transactions with owners of the Company

Contribution of loans from related parties			-		16,494,413		-		-			16,494,413
Capital increase			-		1,000,000		-		-			1,000,000
Balance at December 31, 2023			3,000,000		17,494,413		138,583		(20,726,382	)		(93,386	)

	Note	2023
Cash flows from operating activities
Net loss			(1,779,505	)
Adjustments for:
Income tax gain			(98,872	)
			(1,878,377	)
Changes in:
Inventories			(319,416	)
Trade and other receivables			361,112
Prepayments			404,046
Trade and other payables			1,465,502
Accrued expenses			(548,997	)
Net cash used in operating activities			(516,130	)

Cash flows from investing activities
Other financial assets			2,065
Net cash from investing activities			2,065

Cash flows from financing activities
Capital increase	10		1,000,000
Net cash from financing activities			1,000,000

Net increase in cash and cash equivalents			485,935
Cash and cash equivalents at beginning of the period			4,950
Net effect of currency translation on cash			(497	)
Cash and cash equivalents at end of the period			490,388

		Geographical	Reporting	December 31,		December 31,
Currency		area	entities	2023		2022
CHF	Swiss Franc	Switzerland	1		1.0000		1.0000
USD	Dollar	United States	0		0.8451		0.9251
EUR	Euro	Europe	0		0.9287		0.9901
AUD	Dollar	Australia	1		0.5735		0.6305

*	Filed herewith

**	Previously filed

IFRS 17	Insurance contracts

IAS 1	Amendments to IAS 1 and IFRS practice Statement 2, Disclosure of Accounting Policies

IAS 8	Amendments to IAS 8, Definition of Accounting Estimates

IAS 12	Amendments to IAS 12, Deferred tax related to Assets and Liabilities arising from a Single Transaction

IAS 12	Amendment to IAS 12, International Tax Reform – Pillar Two Model Rules

						Planned
						application
				Effective		by the
Standard/Interpretation		Impact		date		Company
New standards, interpretations or amendments
IFRS 16	Amendments to IFRS 16, Liability in a Sale and Leaseback		1)		January 1,	FY 2024
					2024

IAS 1	Amendments to IAS 1, Classification of Liabilities as Current or Non-current		1)		January 1,	FY 2024
					2024

IAS 1	Amendments to IAS 1, Non-current liabilities with covenants		1)		January 1,	FY 2024
					2024

IAS 7	Amendments to IAS 7, Supplier finance agreements		1)		January 1,	FY 2024
					2024

IAS 21	Amendments to IAS 21, Lack of Exchangeability		1)		January 1,	FY 2025
					2025

	December 31,
	2023
Financial assets
At amortized cost
Cash and cash equivalents		490,388
Trade receivables		100,392
Other receivables		4,053
Other non-current financial assets		102,157
Total financial assets		696,990

Financial liabilities
At amortized cost
Loan		18,905
Trade and other payables		327,582
Accrued expenses		60,840
Total financial liabilities		407,327

					Between
	Carrying		Less than		3 months and		2 years and
	amount		3 months		2 years		later		Total
December 31, 2023
Trade and other payables		327,582		327,582		-		-		327,582
Accrued expenses		60,840		60,840		-		-		60,840
Loan		-		18,905		-		-		18,905
Total		388,422		407,327		-		-		407,327

	2023
in CHF	USD			EUR			AUD
Cash and cash equivalents		10,651			19,334			-
Trade and other receivables		-			100,392			-
Inter-company loan		-			-			1,744,686
Other non-current financial assets		-			102,157			-
Trade and other payables		(3,489	)		(22,447	)		(54,567	)
Accrued expenses		-			(52,893	)		-
Net statement of financial position exposure - asset/(liability)		7,162			146,543			1,690,119

	December 31,
	2023
Finished goods		109,991
Raw materials		217,283
Advance payments		3,787
Total		331,061

	December 31,
	2023
R&D tax credit receivable		220,041
Value added tax receivable		58,722
Receivable from suppliers and other		4,053
Total other receivables		282,816

	December 31,
	2023
Advance payments to suppliers		171,995
Total prepayments		171,995

	December 31,
	2023
Cash in bank accounts		490,388
Total cash and cash equivalents		490,388

	December 31,
	2023
	Number		CHF
Common shares with a par value of CHF 1.00 each		3,000,000		3,000,000
Total		3,000,000		3,000,000

	Common Shares
	(Number)
		2023
As of January 1		3,000,000
As of December 31		3,000,000

	December 31,
	2023
Trade and other payable - third parties		327,582
Total trade and other payables		327,582

	December 31,
	2023
Accrued deliveries and services from suppliers		60,840
Total accrued expenses		60,840

	December 31,
	2023
Upfront payment		932,200
Total deferred income		932,200

	2023
Product purchases, packaging and logistics		171,496
Inventory write-down		54,393
Total cost of sales		225,889

	2023
Income from R&D tax incentive (Government grant)		134,075
Total other operating income		134,075

	2023
Clinical projects		712,399
Quality assurance		124,112
Patents and trademarks		78,089
Regulatory projects		42,198
R&D costs charged by related party		459,988
Other R&D costs		8,588
Total research and development		1,425,373

	2023
Marketing and sales expenses		61,630
Administration expenses		105,012
SG&A costs charged by related party		192,493
Other selling, general and administrative		13,343
Total general and administrative		372,479

	2023
Interest income – third parties		127
Interest income – related party		1,889
Foreign currency exchange gain		285,015
Total finance income		287,032
Interest expense – third parties		2,647
Interest expense – related party		301,726
Foreign exchange loss		120,368
Bank charges		9,215
Total finance expense		433,956
Finance expense, net		(146,924	)

	2023
Deferred income tax expense		-
Deferred income tax gain		98,872
Income tax gain		98,872

	2023
Accounting Loss before income tax		(1,878,377	)
Income tax at the Company’s statutory tax rate		265,020
Effect of unrecognized taxable losses		(265,020	)
Effect of unrecognized temporary differences		71,066
Other effects		27,806
Income tax gain		98,872

	December 31,
	2023
Within 1 year		-
Between 1 and 3 years		-
Between 3 and 7 years		(18,032,979	)
More than 7 years		-
Total		(18,032,979	)